Form 4: Vir Biotechnology Director Robert J. More Reports Stock Transfers Related to RSU Vesting

Vir Biotechnology Director Robert J. More reported the transfer of 14,027 shares of common stock for no consideration to Alta Partners NextGen Fund I, L.P. in connection with RSU award vesting, impacting both his direct and indirect holdings.

Summary

• Robert J. More, a Director of Vir Biotechnology, Inc., reported transactions involving the company's common stock on June 9, 2025.
• He disposed of 14,027 shares of common stock directly for no consideration, reducing his direct beneficial ownership to 40,656 shares.
• Concurrently, 14,027 shares were acquired indirectly for no consideration, increasing the indirect beneficial ownership to 509,917 shares.
• These transactions were transfers to Alta Partners NextGen Fund I, L.P. (APNG 1) in connection with the vesting of Restricted Stock Unit (RSU) awards.
• Mr. More is a managing director of the general partner of APNG 1 and disclaims beneficial ownership of these indirectly held shares, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction related to RSU vesting and a transfer between related entities, not a market-driven sale or purchase. It reflects compensation structure rather than a change in sentiment.

Positives

• The transaction is related to the vesting of RSU awards, indicating compensation for the director.
• The shares remain within an entity where the director has an indirect interest, suggesting continued alignment with the company's performance.

Negatives

• The direct beneficial ownership of the reporting person decreased by 14,027 shares.

Management Comments

• Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards.
• The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.

Related Party Transactions

• Transfer of shares from Robert J. More to Alta Partners NextGen Fund I, L.P. (APNG 1), where Mr. More is a managing director of the general partner.

Stakeholder Impact

• Shareholders: Minor impact as it's a compensation-related transfer, not a market sale. It clarifies the beneficial ownership structure of a director's equity.

Key Dates

Keywords

Vir Biotechnology, VIR, SEC Form 4, Insider Trading, Stock Ownership, Director, RSU Vesting, Equity Compensation, Alta Partners